Peginterferon alfacon-1

Drug Profile

Peginterferon alfacon-1

Alternative Names: PEG INF alfacon-1; PEG-Alfacon; PEG-Infergen; PEG-interferon alfacon-1; Pegylated interferon alfacon-1

Latest Information Update: 04 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 13 Mar 2006 Discontinued - Phase-II for Hepatitis C in USA (SC)
  • 13 Mar 2006 Discontinued - Preclinical for Hepatitis C in Canada (SC)
  • 03 Jun 2005 Data presented at the Digestive Disease Week and the 106th Annual Meeting of the American Gastroenterological Association (DDW-2005) have been added to the adverse events, pharmacokinetics and Viral infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top